Immix Biopharma, Inc(IMMX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IMMX Immix Biopharma, Inc

盘前交易 04-16 04:44:11 EDT

10.04

+0.19

+1.93%

最高10.16	最低9.73	成交量61.74万
今开9.85	昨收9.85	日振幅4.37%
总市值5.32亿	流通市值4.16亿	总股本5,296万
成交额615.47万	换手率1.49%	流通股本4,144万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IMMX","market":"US","secType":"STK","nameCN":"Immix Biopharma, Inc","latestPrice":10.04,"timestamp":1776283200000,"preClose":9.85,"halted":0,"volume":617419,"delay":0,"changeRate":0.019289340101522792,"floatShares":41439399,"shares":52955100,"eps":-0.893007,"marketStatus":"盘前交易","change":0.19,"latestTime":"04-16 04:44:11 EDT","open":9.85,"high":10.16,"low":9.73,"amount":6154694.377656001,"amplitude":0.043655,"askPrice":11.12,"askSize":100,"bidPrice":10.05,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.893007,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776346200000},"marketStatusCode":1,"adr":0,"listingDate":1639630800000,"exchange":"NASDAQ","adjPreClose":10.04,"postHourTrading":{"tag":"盘后","latestPrice":10,"preClose":10.04,"latestTime":"19:45 EDT","volume":2976,"amount":29882.7238,"timestamp":1776296704387,"change":-0.04,"changeRate":-0.003984,"amplitude":0.012998},"volumeRatio":1.035912543151521,"impliedVol":1.0911,"impliedVolPercentile":0.3735},"requestUrl":"/m/hq/s/IMMX","defaultTab":"news","newsList":[{"id":"1158867508","title":"默沙东与Infinimmune达成协议 获得抗体候选药物独家开发及商业化权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1158867508","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158867508?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:08","pubTimestamp":1774958923,"startTime":"0","endTime":"0","summary":"根据最新合作协议，默沙东（MRK）将获得Infinimmune公司抗体候选药物的独家开发及商业化权利。该协议标志着双方在创新疗法领域的重要战略合作，为默沙东的研发管线注入新的生物技术资产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2361044949.HKD","IE00BLSP4239.USD","LU2360032135.SGD","LU0868494617.USD","IE0002141913.USD","LU1291159041.SGD","LU2125154935.USD","LU0965509283.SGD","LU2089984988.USD","IE00B4R5TH58.HKD","LU1941712264.USD","LU0203347892.USD","LU1066053197.SGD","SG9999014559.SGD","BK4559","LU1989772840.SGD","LU0238689110.USD","LU2361044865.SGD","LU1116320737.USD","LU0208291251.USD","LU0432979614.USD","IE00B2B36J28.USD","SG9999001176.USD","IE00BJT1NW94.SGD","IE00BLSP4452.SGD","LU2361045086.USD","LU2125154778.USD","LU0006306889.USD","LU1057294990.SGD","SG9999015358.SGD","LU1585245621.USD","SG9999002224.SGD","LU2023250504.SGD","LU0106261372.USD","LU0058720904.USD","LU0266013472.USD","LU0211331839.USD","SG9999014567.USD","IE00B1BXHZ80.USD","LU1093756325.SGD","BK4550","LU1430594728.SGD","LU2112291526.USD","SG9999014542.SGD","LU2023250843.SGD","SGXZ57979304.SGD","LU1035773651.USD","LU1699723380.USD","LU0965508806.USD","LU1934455277.USD","BK4534","LU0985320562.USD","LU0477156953.USD","LU1061106388.HKD","LU0234572021.USD","LU1571399168.USD","LU0203345920.USD","LU1941712348.USD","LU2468319806.SGD","IE0009355771.USD","LU1989771016.USD","SG9999001176.SGD","IE00BJJMRZ35.SGD","BK4516","LU0965509010.AUD","LU1974910355.USD","LU0320765646.SGD","LU2324357040.USD","LU1066051498.USD","LU0130102774.USD","LU1069347547.HKD","IE000M9KFDE8.USD","LU1934455194.USD","LU0942090050.USD","LU1023059063.AUD","LU1162221912.USD","BK4007","LU1989772923.USD","LU1037948541.HKD","SG9999015341.SGD","LU0070302665.USD","LU1201861249.SGD","LU1037948897.HKD","SG9999013999.USD","LU2106854487.HKD","IE00BN8TJ469.HKD","LU0289739699.SGD","LU1983299246.USD","IE00BBT3K403.USD","LU0868494708.USD","SG9999014575.USD","LU0980610538.SGD","BK4588","LU1934455863.HKD","IE00BSNM7G36.USD","MRK","IE00BFTCPJ56.SGD","LU1093756168.USD","BK4585","LU0648001328.SGD","LU1929549753.HKD","LU1066051225.USD","LU0098860793.USD","LU0130517989.USD","LU0965509101.SGD","LU0265550946.USD","LU0861579265.USD","LU2461242641.AUD","LU1066051811.HKD","SG9999001440.SGD","IMMX","LU0320765489.SGD","LU1917777945.USD","BK4533","SG9999002232.USD","LU1116320901.HKD","LU0265550359.USD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140197538","title":"Immix Biopharma宣布完成BLA支持性复发/难治性AL淀粉样变性试验Nexicart-2的患者入组及即将到来的里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1140197538","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140197538?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:47","pubTimestamp":1774874837,"startTime":"0","endTime":"0","summary":"Immix Biopharma, Inc. 已宣布其用于支持生物制品许可申请（BLA）的复发/难治性AL淀粉样变性试验Nexicart-2的患者入组工作顺利完成。该试验的完成标志着公司向监管审批迈出了关键一步。与此同时，公司还公布了接下来的一系列重要研发里程碑，预示着其在AL淀粉样变性治疗领域的持续进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174396373","title":"Immix Biopharma公司于2026年3月25日签订ATM发行协议第一号修正案 - 美国证券交易委员会文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1174396373","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174396373?lang=zh_cn&edition=full","pubTime":"2026-03-26 05:26","pubTimestamp":1774473977,"startTime":"0","endTime":"0","summary":"Immix Biopharma公司于2026年3月25日，就其ATM（按市价发行）发行协议签订了第一号修正案。此项信息已在美国证券交易委员会（SEC）的相关文件中披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614098358","title":"Immix Biopharma, Inc.盘中异动 快速上涨5.18%报8.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614098358","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614098358?lang=zh_cn&edition=full","pubTime":"2026-02-25 23:03","pubTimestamp":1772031831,"startTime":"0","endTime":"0","summary":"北京时间2026年02月25日23时03分，Immix Biopharma, Inc.股票出现波动，股价急速上涨5.18%。截至发稿，该股报8.93美元/股，成交量12.2318万股，换手率0.23%，振幅4.53%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.15%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。其候选产品包括治疗自身免疫性疾病的 CAR-T NXC-201 和治疗软组织肉瘤的 IMX-110。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225230352a4c7bd2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225230352a4c7bd2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608457428","title":"Immix Biopharma, Inc.盘中异动 早盘股价大涨5.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608457428","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608457428?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:59","pubTimestamp":1770044347,"startTime":"0","endTime":"0","summary":"北京时间2026年02月02日22时59分，Immix Biopharma, Inc.股票出现波动，股价快速拉升5.80%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.82%。其相关个股中，Psyence Biomedical Ltd.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Celularity Inc C/Wts 16/07/2026 涨幅较大，60 Degrees Pharmaceuticals, Inc.、Vivosim Labs, Inc.、Vyome Holdings, Inc.较为活跃，换手率分别为255.44%、22.77%、16.83%，振幅较大的相关个股有60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Psyence Biomedical Ltd.、Bioatla, Inc.，振幅分别为82.69%、58.49%、40.48%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202225907a473cf70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202225907a473cf70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607722485","title":"Immix Biopharma, Inc.盘中异动 股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607722485","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607722485?lang=zh_cn&edition=full","pubTime":"2026-01-29 03:25","pubTimestamp":1769628325,"startTime":"0","endTime":"0","summary":"北京时间2026年01月29日03时25分，Immix Biopharma, Inc.股票出现波动，股价快速上涨5.05%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.68%。其相关个股中，Jasper Therapeutics Inc C/Wts 24/09/2026 、Moolec Science Sa C/Wts 30/01/2028、Psyence Biomedical Ltd.涨幅较大，Gri Bio, Inc.、Calcimedica, Inc.、60 Degrees Pharmaceuticals, Inc.较为活跃，换手率分别为2303.89%、282.51%、147.77%，振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Gri Bio, Inc.、Briacell Therapeutics Corp C/Wts 26/02/2026，振幅分别为90.64%、53.19%、52.83%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129032525953ec9d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129032525953ec9d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592533011","title":"Immix Biopharma, Inc.盘中异动 临近收盘股价大涨5.04%报5.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592533011","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592533011?lang=zh_cn&edition=full","pubTime":"2025-12-19 04:42","pubTimestamp":1766090528,"startTime":"0","endTime":"0","summary":"北京时间2025年12月19日04时42分，Immix Biopharma, Inc.股票出现波动，股价大幅上涨5.04%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.52%。其相关个股中，Protagenic Therapeutics Inc C/Wts 26/04/2026 、Athira Pharma, Inc.、Greenwich Lifesciences, Inc.涨幅较大，Athira Pharma, Inc.、Biodexa Pharmaceuticals Plc、Aditxt, Inc.较为活跃，换手率分别为1506.98%、304.99%、116.60%，振幅较大的相关个股有Protagenic Therapeutics Inc C/Wts 26/04/2026 、健永生技、Lexaria Bioscience Corp C/Wts 14/01/2026 ，振幅分别为65.12%、45.85%、44.39%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219044209953b6d4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219044209953b6d4d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117468197","title":"Immix Biopharma 宣布增加至 1 亿美元的承销普通股及预先融资认股权证的定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1117468197","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117468197?lang=zh_cn&edition=full","pubTime":"2025-12-08 07:21","pubTimestamp":1765149699,"startTime":"0","endTime":"0","summary":"Immix Biopharma 宣布增加至 1 亿美元的承销普通股及预先融资认股权证的定价","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174180157","title":"Immix Biopharma在ASH 2025口头报告中公布Nxc-201第二阶段积极结果，向BLA提交迈进，有望成为复发/难治AL淀粉样变性的一流最佳治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1174180157","media":"美股速递","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174180157?lang=zh_cn&edition=full","pubTime":"2025-12-08 07:15","pubTimestamp":1765149347,"startTime":"0","endTime":"0","summary":"Immix Biopharma在ASH 2025口头报告中公布了Nxc-201第二阶段的积极结果，向BLA提交迈进，这一疗法有望成为复发/难治性AL淀粉样变性患者的一流且最佳治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585173266","title":"Immix Biopharma, Inc.盘中异动 急速上涨5.22%报4.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585173266","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585173266?lang=zh_cn&edition=full","pubTime":"2025-11-22 02:48","pubTimestamp":1763750937,"startTime":"0","endTime":"0","summary":"北京时间2025年11月22日02时48分，Immix Biopharma, Inc.股票出现异动，股价急速拉升5.22%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为1.19%。其相关个股中，Celularity Inc C/Wts 16/07/2026 、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025涨幅较大，Osr Holdings, Inc.、Pasithea Therapeutics Corp.、Psyence Biomedical Ltd.较为活跃，换手率分别为454.39%、29.49%、24.07%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Osr Holdings, Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 ，振幅分别为63.22%、49.71%、47.00%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112202485797782828&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112202485797782828&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583954560","title":"Immix Biopharma, Inc.盘中异动 早盘快速下跌5.11%报3.53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583954560","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583954560?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:44","pubTimestamp":1763045049,"startTime":"0","endTime":"0","summary":"北京时间2025年11月13日22时44分，Immix Biopharma, Inc.股票出现异动，股价大幅下挫5.11%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.04%。其相关个股中，Mersana Therapeutics, Inc.、Clearmind Medicine Inc.、Cdt Equity Inc C/Wts 22/09/2028涨幅较大，Clearmind Medicine Inc.、Salarius Pharmaceuticals, Inc.、Mersana Therapeutics, Inc.较为活跃，换手率分别为2716.67%、318.38%、34.21%，振幅较大的相关个股有Clearmind Medicine Inc.、Cellectar Biosciences, Inc.、Mersana Therapeutics, Inc.，振幅分别为76.93%、15.29%、13.53%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113224409a49f4cb1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113224409a49f4cb1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143753604","title":"Immix Biopharma的Nxc-201 Nexicart-2临床试验结果将在ASH 2025大会上进行口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1143753604","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143753604?lang=zh_cn&edition=full","pubTime":"2025-11-03 21:46","pubTimestamp":1762177588,"startTime":"0","endTime":"0","summary":"Immix Biopharma的Nxc-201 Nexicart-2临床试验结果将在ASH 2025大会上进行口头报告","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2578319049","title":"Immix Biopharma, Inc.盘中异动 股价大跌5.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578319049","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578319049?lang=zh_cn&edition=full","pubTime":"2025-10-27 23:41","pubTimestamp":1761579660,"startTime":"0","endTime":"0","summary":"北京时间2025年10月27日23时41分，Immix Biopharma, Inc.股票出现波动，股价快速下挫5.54%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.68%。其相关个股中，Nls Pharmaceutics Ltd C/Wts 02/02/2026、Surrozen Inc C/Wts 01/08/2031 、Avidity Biosciences, Inc.涨幅较大，Aditxt, Inc.、Nls Pharmaceutics Ltd.、Cellectar Biosciences, Inc.较为活跃，换手率分别为184.49%、155.98%、127.34%，振幅较大的相关个股有Nls Pharmaceutics Ltd C/Wts 02/02/2026、Ethzilla Corporation C/Wts 06/11/2025、Zenas Biopharma, Inc.，振幅分别为81.53%、48.12%、34.32%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251027234101a6d111dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251027234101a6d111dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2575767378","title":"Immix Biopharma, Inc.盘中异动 快速上涨6.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575767378","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575767378?lang=zh_cn&edition=full","pubTime":"2025-10-15 22:05","pubTimestamp":1760537103,"startTime":"0","endTime":"0","summary":"北京时间2025年10月15日22时05分，Immix Biopharma, Inc.股票出现异动，股价大幅上涨6.15%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.15%。其相关个股中，Genprex, Inc.、奥麦罗制药、Apollomics Inc C/Wts 01/04/2028 涨幅较大，Genprex, Inc.、Scisparc Ltd.、奥麦罗制药较为活跃，换手率分别为789.65%、92.47%、78.31%，振幅较大的相关个股有Genprex, Inc.、Apollomics Inc C/Wts 01/04/2028 、奥麦罗制药，振幅分别为128.99%、103.66%、61.71%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251015220503a6baf229&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251015220503a6baf229&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518783692","title":"Immix Biopharma, Inc.盘中异动 早盘股价大涨8.55%报1.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518783692","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518783692?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:54","pubTimestamp":1741614857,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时54分，Immix Biopharma, Inc.股票出现波动，股价急速拉升8.55%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2864.76%、638.63%、141.33%，振幅较大的相关个股有Scisparc Ltd.、Impact Biomedical, Inc.、Trevi Therapeutics, Inc.，振幅分别为40.24%、28.59%、25.35%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021541796403bef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021541796403bef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516573536","title":"Immix Biopharma, Inc.盘中异动 股价大跌6.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516573536","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516573536?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:51","pubTimestamp":1741027863,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时51分，Immix Biopharma, Inc.股票出现异动，股价急速跳水6.68%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Radiopharm Theranostics Limited涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4441.89%、200.42%、179.81%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304025103a25d88ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304025103a25d88ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514062019","title":"Immix Biopharma, Inc.盘中异动 早盘股价大跌5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514062019","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514062019?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:18","pubTimestamp":1740500329,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时18分，Immix Biopharma, Inc.股票出现波动，股价快速下跌5.23%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Organovo Holdings, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Silexion Therapeutics Corp涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1316.81%、1113.72%、895.27%，振幅较大的相关个股有Organovo Holdings, Inc.、Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为224.93%、87.83%、66.67%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226001849a2539f88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226001849a2539f88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513777338","title":"Immix Biopharma, Inc.盘中异动 大幅跳水5.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513777338","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513777338?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:29","pubTimestamp":1740410943,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时29分，Immix Biopharma, Inc.股票出现波动，股价急速跳水5.40%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.29%。其相关个股中，Pepgen Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为202.64%、85.33%、27.77%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ，振幅分别为137.23%、55.69%、53.34%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224232904962ea66a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224232904962ea66a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512196853","title":"Immix Biopharma, Inc.盘中异动 大幅下跌5.56%报1.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512196853","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512196853?lang=zh_cn&edition=full","pubTime":"2025-02-19 02:58","pubTimestamp":1739905107,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日02时58分，Immix Biopharma, Inc.股票出现波动，股价急速跳水5.56%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.45%。其相关个股中，Aditxt, Inc.、Allogene Therapeutics, Inc.、Solid Biosciences Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为805.12%、207.44%、166.74%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.，振幅分别为148.75%、92.00%、79.17%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219025827a24ae432&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219025827a24ae432&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511962316","title":"Immix Biopharma, Inc.盘中异动 早盘急速下跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511962316","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511962316?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:36","pubTimestamp":1739543790,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时36分，Immix Biopharma, Inc.股票出现异动，股价大幅跳水5.03%。Immix Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.24%。其相关个股中，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.涨幅较大，Moleculin Biotech, Inc.、Virpax Pharmaceuticals, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为1235.22%、380.55%、364.53%，振幅较大的相关个股有Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 ，振幅分别为49.61%、21.52%、20.20%。Immix Biopharma, Inc.公司简介：Immix Biopharma Inc 从事发现和开发治疗血液恶性肿瘤（血癌）和其他适应症的新型细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214223631abcf07b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214223631abcf07b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immixbio.com","stockEarnings":[{"period":"1week","weight":0.1474},{"period":"1month","weight":-0.0678},{"period":"3month","weight":1.1316},{"period":"6month","weight":2.4983},{"period":"1year","weight":4.9762},{"period":"ytd","weight":0.9197}],"compareEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.0111},{"period":"6month","weight":0.0535},{"period":"1year","weight":0.3019},{"period":"ytd","weight":0.0264}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Immix Biopharma, Inc.于2014年1月7日成立为特拉华州公司。公司是一家临床阶段的生物制药公司，专注于嵌合抗原受体细胞疗法（“CAR-T”）在轻链（AL）淀粉样变性和自身免疫性疾病中的应用。公司主导细胞治疗候选药物为美国食品药品监督管理局（“FDA”）研究性新药（“IND”）批准的CAR-T NXC-201，目前正在公司进行的1b/2a期NEXICART-1（NCT04720313）临床试验中进行评估。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.035123},{"month":2,"riseRate":0.2,"avgChangeRate":-0.05746},{"month":3,"riseRate":0.2,"avgChangeRate":-0.065433},{"month":4,"riseRate":0.6,"avgChangeRate":-0.001073},{"month":5,"riseRate":0.5,"avgChangeRate":0.112474},{"month":6,"riseRate":0.5,"avgChangeRate":0.09241},{"month":7,"riseRate":0.5,"avgChangeRate":0.015932},{"month":8,"riseRate":0.25,"avgChangeRate":-0.104667},{"month":9,"riseRate":0.25,"avgChangeRate":0.017421},{"month":10,"riseRate":0.75,"avgChangeRate":0.171445},{"month":11,"riseRate":1,"avgChangeRate":0.264693},{"month":12,"riseRate":1,"avgChangeRate":0.380003}],"exchange":"NASDAQ","name":"Immix Biopharma, Inc","nameEN":"Immix Biopharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immix Biopharma, Inc(IMMX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Immix Biopharma, Inc(IMMX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Immix Biopharma, Inc,IMMX,Immix Biopharma, Inc股票,Immix Biopharma, Inc股票老虎,Immix Biopharma, Inc股票老虎国际,Immix Biopharma, Inc行情,Immix Biopharma, Inc股票行情,Immix Biopharma, Inc股价,Immix Biopharma, Inc股市,Immix Biopharma, Inc股票价格,Immix Biopharma, Inc股票交易,Immix Biopharma, Inc股票购买,Immix Biopharma, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immix Biopharma, Inc(IMMX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Immix Biopharma, Inc(IMMX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}